STI Stock Trade Intelligence
1AD

ADALTA LIMITED

Health Care · ASX:1AD
$0.0030
0.00%
Market cap
$8M
Turnover
$635
Last price
$0.0030
Day change
0.00%
Announcements
22
Range, past year
Open 0.003 · Low 0.002 · Now 0.003 · High 0.008
Open 1AD in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

1AD momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-10-13.
Momentum quality
17/100
Wyckoff phase
Accumulation49d
Trend stage
Neutral
1 Day
+0.0%
1 Week
+0.0%
1 Month
+0.0%
1 Year
+0.0%
RSI
47
Avg daily range
27.3%

ADALTA LIMITED scores 17 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 49 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently matching and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -25.0%
  • High volatility (ATR 27.3%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
1AD appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

1AD announcements

Recent price-sensitive releases.
  • 2026-10-05 EW-001 JDC milestone approvals Progress Report
  • 2026-10-01 China Representative Office opens Progress Report | Company Administration - Other
  • 2026-09-23 US FDA grants EW-001 pre-IND meeting Progress Report
  • 2026-09-18 Oribiotech deal validates AdAlta manufacturing strategy Progress Report
  • 2026-09-02 BZDS1901 special access scheme launch in China Progress Report
  • 2026-08-21 Preliminary Final Report Preliminary Final Report
  • 2026-08-10 EW-001 IIT study overall survival update Progress Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.